PE20110663A1 - Pirrolidinas - Google Patents
PirrolidinasInfo
- Publication number
- PE20110663A1 PE20110663A1 PE2011001004A PE2011001004A PE20110663A1 PE 20110663 A1 PE20110663 A1 PE 20110663A1 PE 2011001004 A PE2011001004 A PE 2011001004A PE 2011001004 A PE2011001004 A PE 2011001004A PE 20110663 A1 PE20110663 A1 PE 20110663A1
- Authority
- PE
- Peru
- Prior art keywords
- optionally substituted
- pyrrolidin
- alkyl
- methyl
- carboxyl
- Prior art date
Links
- 150000003235 pyrrolidines Chemical class 0.000 title 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 3
- -1 4-FLUOROBENZOYL Chemical class 0.000 abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- KHUXNRRPPZOJPT-UHFFFAOYSA-N phenoxy radical Chemical compound O=C1C=C[CH]C=C1 KHUXNRRPPZOJPT-UHFFFAOYSA-N 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE PIRROLIDINA DE FORMULA (I) DONDE R1 ES CICLOALQUILO(C3-C6) O FENILO OPCIONALMENTE SUSTITUIDO CON F, Cl, CN, ALQUILO(C1-C4), ENTRE OTROS; X ES UN ENLACE, NH U O; Z ES COOR2, CONHSO2R3 O CN, EN DONDE R2 ES H O ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON F; R3 ES ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON F; Ar ES UN GRUPO AROMATICO DE 1 A 3 ANILLOS QUE SON FENILO O UN ANILLO HETEROAROMATICO DE 5 O 6 MIEMBROS OPCIONALMENTE SUSTITUIDOS CON F, CN, OH, ALQUILTIO(C1-C6), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO 3-{[(4'-CIANOBIFENIL-4-IL)OXI]METIL}-1-(4-FLUOROBENZOIL)PIRROLIDIN-3-CARBOXILICO; ACIDO 3-{[(4'-CIANOBIFENIL-4-IL)OXI]METIL}-1-(4-METOXIBENZOIL)PIRROLIDIN-3-CARBOXILICO; ACIDO 3-{[4-(5-CLOROPIRIMIDIN-2-IL)FENOXI]METIL}-1-(4-FLUOROBENZOIL)PIRROLIDIN-3-CARBOXILICO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR-2 DE PROSTAGLANDINA E2 (PGE2) O EP2 CON SELECTIVIDAD FRENTE A DP1 Y EP4 SIENDO UTILES EN EL TRATAMIENTO DE ENDOMETRIOSIS, FIBROIDES UTERINOS, ADENOMIOSIS, SINDROME DEL OVARIO POLIQUISTICO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11286908P | 2008-11-10 | 2008-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20110663A1 true PE20110663A1 (es) | 2011-09-23 |
Family
ID=41503565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001004A PE20110663A1 (es) | 2008-11-10 | 2009-10-30 | Pirrolidinas |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8278343B2 (es) |
| EP (1) | EP2364296A1 (es) |
| JP (1) | JP2012508225A (es) |
| KR (1) | KR20110083733A (es) |
| CN (1) | CN102209710A (es) |
| AP (1) | AP2011005728A0 (es) |
| AR (1) | AR074314A1 (es) |
| AU (1) | AU2009312427B2 (es) |
| BR (1) | BRPI0920924A2 (es) |
| CA (1) | CA2741589A1 (es) |
| CL (1) | CL2011001034A1 (es) |
| CO (1) | CO6382112A2 (es) |
| CR (1) | CR20110217A (es) |
| CU (1) | CU20110093A7 (es) |
| DO (1) | DOP2011000127A (es) |
| EA (1) | EA201100549A1 (es) |
| EC (1) | ECSP11011032A (es) |
| GE (1) | GEP20125607B (es) |
| IL (1) | IL212490A0 (es) |
| MA (1) | MA32782B1 (es) |
| MX (1) | MX2011004903A (es) |
| NI (1) | NI201100092A (es) |
| NZ (1) | NZ592311A (es) |
| PA (1) | PA8848001A1 (es) |
| PE (1) | PE20110663A1 (es) |
| SV (1) | SV2011003896A (es) |
| TN (1) | TN2011000211A1 (es) |
| TW (1) | TW201022234A (es) |
| UY (1) | UY32228A (es) |
| WO (1) | WO2010052625A1 (es) |
| ZA (1) | ZA201104310B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201034675A (en) * | 2008-12-18 | 2010-10-01 | Sanofi Aventis | Method for treating macular degeneration |
| TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑 |
| JPWO2013176220A1 (ja) * | 2012-05-25 | 2016-01-14 | 国立大学法人京都大学 | 概日リズム調整 |
| CN110041269A (zh) * | 2019-05-16 | 2019-07-23 | 海门瑞一医药科技有限公司 | 一种2-氯-5-羟基嘧啶的制备方法 |
| WO2022272062A1 (en) * | 2021-06-24 | 2022-12-29 | Reservoir Neuroscience, Inc. | Ep2 antagonist compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3108097B2 (ja) * | 1991-01-21 | 2000-11-13 | 塩野義製薬株式会社 | ３−ベンジリデン−１−カルバモイル−２−ピロリドン類縁体 |
| ES2337887T3 (es) * | 2001-12-20 | 2010-04-30 | Merck Serono Sa | Derivados de pirrolidina en calidad de moduladores de prostaglandina. |
| US8039507B2 (en) * | 2005-06-29 | 2011-10-18 | Allergan, Inc. | Therapeutic substituted gamma lactams |
| US7592364B2 (en) * | 2006-02-28 | 2009-09-22 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| US7550448B2 (en) * | 2006-05-24 | 2009-06-23 | Allergan, Inc. | Therapeutic compounds |
| DE102006039912A1 (de) * | 2006-08-25 | 2008-03-20 | Bayer Healthcare Ag | Substituierte Spirotetronsäuren und ihre Verwendung |
| CN101679235A (zh) * | 2007-05-10 | 2010-03-24 | 辉瑞有限公司 | 氮杂环丁烷衍生物和它们作为前列腺素e2拮抗剂的用途 |
-
2009
- 2009-10-30 PE PE2011001004A patent/PE20110663A1/es not_active Application Discontinuation
- 2009-10-30 AU AU2009312427A patent/AU2009312427B2/en not_active Ceased
- 2009-10-30 MX MX2011004903A patent/MX2011004903A/es active IP Right Grant
- 2009-10-30 JP JP2011535189A patent/JP2012508225A/ja not_active Ceased
- 2009-10-30 CA CA2741589A patent/CA2741589A1/en not_active Abandoned
- 2009-10-30 NZ NZ592311A patent/NZ592311A/xx not_active IP Right Cessation
- 2009-10-30 WO PCT/IB2009/054824 patent/WO2010052625A1/en not_active Ceased
- 2009-10-30 GE GEAP200912219A patent/GEP20125607B/en unknown
- 2009-10-30 AP AP2011005728A patent/AP2011005728A0/xx unknown
- 2009-10-30 KR KR1020117013231A patent/KR20110083733A/ko not_active Abandoned
- 2009-10-30 CN CN2009801446055A patent/CN102209710A/zh active Pending
- 2009-10-30 BR BRPI0920924A patent/BRPI0920924A2/pt not_active IP Right Cessation
- 2009-10-30 EP EP09756838A patent/EP2364296A1/en not_active Withdrawn
- 2009-10-30 EA EA201100549A patent/EA201100549A1/ru unknown
- 2009-11-06 US US12/613,771 patent/US8278343B2/en not_active Expired - Fee Related
- 2009-11-09 TW TW098137955A patent/TW201022234A/zh unknown
- 2009-11-09 PA PA20098848001A patent/PA8848001A1/es unknown
- 2009-11-09 UY UY0001032228A patent/UY32228A/es not_active Application Discontinuation
- 2009-11-10 AR ARP090104350A patent/AR074314A1/es not_active Application Discontinuation
-
2011
- 2011-04-25 CU CU20110093A patent/CU20110093A7/es unknown
- 2011-04-26 CR CR20110217A patent/CR20110217A/es unknown
- 2011-04-26 IL IL212490A patent/IL212490A0/en unknown
- 2011-04-29 TN TN2011000211A patent/TN2011000211A1/fr unknown
- 2011-05-05 EC EC2011011032A patent/ECSP11011032A/es unknown
- 2011-05-06 DO DO2011000127A patent/DOP2011000127A/es unknown
- 2011-05-06 SV SV2011003896A patent/SV2011003896A/es unknown
- 2011-05-09 NI NI201100092A patent/NI201100092A/es unknown
- 2011-05-09 CL CL2011001034A patent/CL2011001034A1/es unknown
- 2011-05-10 MA MA33829A patent/MA32782B1/fr unknown
- 2011-05-11 CO CO11058068A patent/CO6382112A2/es not_active Application Discontinuation
- 2011-06-09 ZA ZA2011/04310A patent/ZA201104310B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009312427B2 (en) | 2011-10-20 |
| CA2741589A1 (en) | 2010-05-14 |
| US20100120793A1 (en) | 2010-05-13 |
| WO2010052625A1 (en) | 2010-05-14 |
| AP2011005728A0 (en) | 2011-06-30 |
| AR074314A1 (es) | 2011-01-05 |
| ZA201104310B (en) | 2012-02-29 |
| NI201100092A (es) | 2011-10-31 |
| AU2009312427A1 (en) | 2010-05-14 |
| CU20110093A7 (es) | 2012-01-31 |
| DOP2011000127A (es) | 2011-07-15 |
| CO6382112A2 (es) | 2012-02-15 |
| UY32228A (es) | 2010-06-30 |
| EP2364296A1 (en) | 2011-09-14 |
| US8278343B2 (en) | 2012-10-02 |
| BRPI0920924A2 (pt) | 2016-10-04 |
| TN2011000211A1 (fr) | 2012-12-17 |
| MX2011004903A (es) | 2011-05-30 |
| SV2011003896A (es) | 2011-07-05 |
| CN102209710A (zh) | 2011-10-05 |
| CL2011001034A1 (es) | 2011-11-11 |
| TW201022234A (en) | 2010-06-16 |
| NZ592311A (en) | 2012-12-21 |
| JP2012508225A (ja) | 2012-04-05 |
| EA201100549A1 (ru) | 2011-12-30 |
| MA32782B1 (fr) | 2011-11-01 |
| CR20110217A (es) | 2011-05-12 |
| IL212490A0 (en) | 2011-06-30 |
| KR20110083733A (ko) | 2011-07-20 |
| PA8848001A1 (es) | 2010-06-28 |
| GEP20125607B (en) | 2012-08-10 |
| ECSP11011032A (es) | 2011-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
| PE20050948A1 (es) | Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv | |
| PE20091843A1 (es) | Inhibidores de catepsina c | |
| AR043015A1 (es) | Compuestos moduladores de amida derivada de quinolina del receptor vanilloide vr1, composiciones farmaceuticas y veterinarias que los contienen y su uso en el tratamiento de enfermedades afectadas por la modulacion de dichos receptores | |
| PE20130311A1 (es) | Composiciones y metodos para modular la via de senalizacion de wnt | |
| PE20120911A1 (es) | Derivados de prolina como inhibidores de catepsina | |
| PE20130281A1 (es) | Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae | |
| PE20081836A1 (es) | Derivados de piperidina como inhibidores de la sintasa de acido graso | |
| ES2561425T3 (es) | (Aza)ciclohexanos carbonilados como ligandos de receptor D3 de la dopamina | |
| PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
| PE20120024A1 (es) | DERIVADOS DE LA PIRIDINA SUSTITUIDO CON ANILLO HETEROCICLICO Y GRUPO y- GLUTAMINICO, Y AGENTES ANTIFUNGALES QUE LOS CONTIENEN | |
| PE20130375A1 (es) | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos | |
| AR060489A1 (es) | Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol | |
| MX2010003849A (es) | Antagonistas de cgrp. | |
| AR077818A1 (es) | Composiciones pesticidas | |
| PE20090326A1 (es) | Compuestos heterociclos como inhibidores de erk | |
| PE20091828A1 (es) | Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino como inhibidores de edg-2 | |
| PE20070343A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
| PE20120258A1 (es) | Derivados de bencimidazol-pirrolidina como inhibidores del virus de la hepatitis c | |
| AR068115A1 (es) | Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida | |
| PE20110591A1 (es) | Composicion farmaceutica estabilizada a base de un compuesto no peptidico | |
| PE20120620A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
| PE20110854A1 (es) | DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1 | |
| PE20091413A1 (es) | (DIHIDRO)PIRROLO[2,1-a] ISOQUINOLINAS | |
| PE20081345A1 (es) | Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |